Thursday, 19 April 2018 - 10:22
  • it
  • de
  • en
  • fr

Roche

Good Phase III results for Roche’s Tecentriq

Switzerland-based group Roche yesterday issued a press release announcing that its immunotherapy tecentriq (atezolizumab) has delivered positive results in combination with chemotherapy (carboplatin and Abraxane). The data have been collected during the Phase III IMpower131 clinical trial, conducted on patients…

Roche pursuing M&A again: Flatiron Health acquired for $1.9bn

Switzerland-based multinational Roche announced yesterday evening, after trading closed, that it has acquired Flatiron Health for $1.9bn. Flatiron is a start-up focusing on cancer treatment technology, developing tools such as the electronic health record (EHR) software and real-world evidence for…

New developments for Roche’s novel autism therapy

FDA has granted Breakthrough Therapy designation to Roche’s RG7314 investigational therapy (balovaptan), developed by the Switzerland-based group for the treatment of autism. Balovaptan is a V1A receptor antagonist, which has already shown efficacy against autism in various clinical trials. Roche’s…

Roche granted approval for ocrelizumab (multiple sclerosis) in Europe

Roche has announced that the European Commission has granted a marketing authorization to ocrelizumab, for the treatment of patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The European Commission has considered the positive results from the…

Roche – General Electric strategic collaboration announced

Pharma group Roche yesterday announced an agreement with the US-based giant General Electric Healthcare (GE). The partnership is aimed at developing a new software for the treatment of patients with advanced-stage cancer. The data will reportedly be collected from GE’s…

A detailed analysis of the biosimilars market

The Basel-based daily Neue Zürcher Zeitung has published a long article about the biosimilars market and its dynamics. Biotech companies are developing at a rate with few equals and delivered revenues of approximately $100bn in the US in 2017, which…

Excellent momentum of Idorsia continues, shares rise

The Swiss biotech Idorsia keeps surprising analysts and investors with excellent financial performances and strategic decisions. Its shares have increased by over 34% over the last three months, taking its capitalization to CHF2.76bn. Moreover, Idorsia before Christmas entered into a…

Acquisition of Ignyta fetches almost $100m to Teva from Roche

Israel-based Teva has unexpectedly received a cash injection as Roche has acquired Ignyta for $1.7bn, thanks to Teva owning 5% of the American biotech’s shares. Teva sold to Ignyta the rights to four cancer drugs in March 2015, in return…

Roche’s and Bayer’s strategies compared

If we compare the pipelines and M&A activities of Germany-based Bayer and Switzerland-based Roche, it is clear that the strategies developed by the two groups have much in common.  Bayer signed on November 14th an agreement with Loxo Oncology worth…

Roche pursuing M&A again: Ignyta acquired for $1.7bn

Switzerland-based Roche today has surprised the market as it has announced the acquisition of California-based (San Diego) Ignyta for $1.7bn. Ignyta was founded in 2011 and focuses on the so-called Precision Therapeutics area, addressing the challenge to find treatments to…

Outstanding results from Tecentriq-Avastin combo therapy for lung cancer treatment

All large companies operating in oncology are nowadays testing therapies combining a traditional cancer treatment with a new-generation one. Roche yesterday announced the results from Phase-III IMpower150 clinical trial, testing Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a treatment…

FDA approves Roche’s Hemlibra, novel therapy for hemophilia A

Roche has announced that FDA has approved Hemlibra (emicizumab) for routine prophylaxis in adults and children with haemophilia A with factor VIII inhibitors.  Approximately 30% of haemophilia A patients can develop inhibitors against factor VIII replacement therapies. This puts them…

Pharma sector dynamics and Roche’s strategy

The pharmaceutical market maintains its consolidation trend, as confirmed by recent figures from Evaluate Pharma. The global drug market was worth $770bn in 2016 and as much as 20% of this value was generated by the top 4 of the…

Two FDA approvals in one day for Roche

There was a spate of good news for Switzerland’s Roche yesterday. FDA granted marketing approval to two therapies. The former is Zelboraf (vemurafenib), for the treatment of Erdheim-Chester Disease, a rare type of blood cancer – as few as 600-700…

An analysis of Roche two days after Q3 2017 results publication

The German daily Finanz und Wirtschaft today published a long analysis of the Switzerland-based pharmaceutical group Roche, two days after it announced its third-quarter results. Analysts are now expecting that the positive performance already reported in the second quarter is…

The evolution of blockbuster business according to JP Morgan

The research for new blockbusters has always been a priority for large pharma groups – a trend expected to continue. According to JP Morgan, an increasing number of drugs from the new category referred to as “personalized and precision medicine”…

Impact of biosimilars on Roche’s sales (CHF10bn)

Reuters today published a report assessing the impact of the new Roche biosimilar class on the company’s sales. The three blockbusters by Roche – Rituxan, Herceptin and Avastin – generated CHF20.9bn in 2016, that is approximately 50% of the group’s…

Roche announces sale of plant with 200 employees to Recipharm

Roche has sold its Leganés (Spain) manufacturing site to Sweden-based Recipharm AB. The plant delivers a revenue of almost €35m, supplies products to 95 countries and has approximately 200 employees. The facility offers Recipharm opportunity to achieve synergies with its…

Boehringer Ingelheim obtains FDA approval for biosimilar to Humira

Boehringer Ingelheim has obtained approval by the FDA for Cyltezo, the biosimilar to AbbVie’s immunosuppressant Humira. Cyltezo is the first biosimilar by the Germany-based group to be approved and is fairly significant as it provides an alternative to the best-selling…

FDA, priority review for Genentech/Roche’s emicizumab in haemophilia A

Genentech, a member of the Roche Group, announced that FDA accepted a sBLA (Biologics License Application) and granted Priority Review for emicizumab as a prophylaxis treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. As part…